BP

BridgeBio Pharma, Inc.

Q2 FY26Biotechnology

BridgeBio Pharma, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹68

Market cap₹13.4K Cr

P/E204.4

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueGood growth

MarginMargins steady

CapexCapex planned

FundraiseNo fundraise planned

The short version

- Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth in Q1 2026. - BridgeBio expects operating losses to flatten over the next two quarters due to ramping up launch activities for upcoming products.

From BridgeBio Pharma, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Good growth

Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth in Q1 2026.
New patient starts and first-line share gains are accelerating, driving market momentum.
Attruby expected to be a $4 billion drug with potential upside, continuing growth even beyond 2032.
Three near-term launches—LGMD2I, ADH1, and achondroplasia—are progressing with strong commercial readiness.
LGMD2I entering a disease area with no approved therapy; high patient engagement predicted.
ADH1 market building aided by claims analysis and genetic testing identifying patients.
Achondroplasia launch supported by strong Phase III data and high physician awareness.

2 more points from BridgeBio Pharma, Inc.'s call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

BridgeBio expects operating losses to flatten over the next two quarters due to ramping up launch activities for upcoming products.
By end of 2027, the company targets transitioning to operating profit breakeven followed by sustainable cash flow positivity.
Attruby's net sales showed strong growth (24% quarter-over-quarter, 392% year-over-year), driving revenue increases.
Investments continue in launches and pipeline programs, but with disciplined OpEx management resulting in more than 50% narrowing of operating losses over five quarters.
The company has significant cash reserves (~$940 million) to fund operations and growth.
Share repurchase program authorized ($500 million) to enhance shareholder value without compromising operational funding.

2 more points from BridgeBio Pharma, Inc.'s call on margins

Pro opens every point from 15K+ earnings calls

See what BridgeBio Pharma, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

BridgeBio is focused on executing its current pipeline, including launches of AV H1, LGMD2I, and achondroplasia, ensuring high-quality regulatory submissions and commercial readiness.
The company sees significant additional opportunities by leveraging existing drug products, such as Attruby, and internal pipeline programs (ADPKD, cardiomyopathy, antibody programs).
BridgeBio maintains a disciplined capital approach, prioritizing investment in its own pipeline and launches rather than aggressive external acquisitions or broad dilution.
The Board authorized a $500 million share repurchase program as an opportunistic, additive use of capital alongside continued investment in clinical trials and launches.

2 more points from BridgeBio Pharma, Inc.'s call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

The company currently has a strong cash position of $940.2 million, providing significant runway to fund operations, advance programs, and invest in growth.
There is no explicit mention of plans for new fundraising through debt or equity in the near term.
The results indicate a focus on financial discipline and leveraging existing resources for launches and pipeline advancement.

2 more points from BridgeBio Pharma, Inc.'s call on fundraising

Pro opens every point from 15K+ earnings calls

See what BridgeBio Pharma, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript does not explicitly mention specific current or expected orderbook or pending orders for BridgeBio Pharma. However, commercially relevant points include: - Strong commercial and medical leadership established for infigratinib and achondroplasia. - Ongoing efforts to raise awareness among pediatric endocrinologists and specialized centers. - High unaided awareness (~40%) in the prescribing physician community for achondroplasia. - Attruby franchise showing continued momentum with accelerating patient starts (6,100 new patient starts in Q1 2026). - Significant patient outreach and inbound inquiries for limb-girdle muscular dystrophy following NDA submission.

2 more points from BridgeBio Pharma, Inc.'s call on order book

Pro opens every point from 15K+ earnings calls

Others in Biotechnology this season

Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a

Compare:vs AbbVie Inc.vs Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

BridgeBio Pharma, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were BridgeBio Pharma, Inc. Q2 FY26 results?

- Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth in Q1 2026. - BridgeBio expects operating losses to flatten over the next two quarters due to ramping up launch activities for upcoming products.

What is BridgeBio Pharma, Inc. share price analysis?

BridgeBio Pharma, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 204.4 with a market cap of $13,396. Investors should review the full earnings analysis for detailed insights.

Is BridgeBio Pharma, Inc. planning capital expenditure?

- BridgeBio is focused on executing its current pipeline, including launches of AV H1, LGMD2I, and achondroplasia, ensuring high-quality regulatory submissions and commercial readiness.

Keep BridgeBio Pharma, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.